Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines

British Journal of Cancer

Volumn 88, Issue 12, 2003, Pages 1963-1970

  Bergman, A M ^a   Pinedo, H M ^a   Talianidis, I ^b   Veerman, G ^a   Loves, W J P ^a   Van Der Wilt, C L ^a   Peters, G J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b INSTITUTE OF MOLECULAR BIOLOGY AND BIOTECHNOLOGY   (Greece)

Author keywords

Collateral sensitivity; Deoxycytidine kinase; Gemcitabine; Multidrug resistance; Thymidine kinase

Indexed keywords

COLCHICINE; DEOXYCYTIDINE KINASE; DEOXYCYTIDINE PHOSPHATE DEAMINASE; DNA; GEMCITABINE; GLYCOPROTEIN P; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; THYMIDINE KINASE; VERAPAMIL;

ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DNA DAMAGE; DRUG SENSITIVITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MELANOMA CELL; MULTIDRUG RESISTANCE; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; STRESS;

CELL DIVISION; DEOXYCYTIDINE; DNA DAMAGE; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASMS; P-GLYCOPROTEIN; PHOSPHORYLATION; TUMOR CELLS, CULTURED;

EID: 0038235998     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601011     Document Type: Article

References (66)

1. Abratt RP, Rezwoda W, Falkson G, Goedhals L, Hacking D (1994) Efficacy and safety profile of gemcitabine in non-small cell lung cancer. Phase II study. J Clin Oncol 12: 1535-1540
2. Aszalos A, Thompson K, Yin JJ, Ross DD (1999) Combinations of P-glycoprotein blockers, verapamil, PSC833, and cremophor act differently on the multidrug resistance associated protein (MRP) and on P-glycoprotein (P-gP). Anticancer Res 19: 1053-1064
3. Baker CH, Banzon J, Bollinger JM, Stubbe J (1991) 2′-Deoxy-2′-methylenecytidine and 2′-deoxy-2′,2′-difluorodeoxycytidine 5′-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase. J Med Chem 34: 1879-1884
4. Beck J, Bohnet B, Brugger D, Bader P, Dietl J, Scheper RJ, Kandolf R, Liu C, Niethammer D, Gekeler V (1998) Multiple gene expression analysis reveals distinct differences between G2 and G3 stage breast cancers, and correlations of PKC eta with mdr1, MRP and LRP gene expression. Br J Cancer 77: 87-91
5. Bergman AM, Giaccone G, Van Moorsel CJ, Mauritz R, Noordhuis P, Pinedo HM, Peters GJ (2000) Cross-resistance in the 2′,2′-difluorodeoxycytidine (gemcitabine) resistant human ovarian cancer cell line AG6000 to standard and investigational drugs. Eur J Cancer 36: 1974-1983
6. Bergman AM, Munch-Petersen B, Jensen PB, Sehested M, Veerman G, Voorn DA, Smid K, Pinedo HM, Peters GJ (2001a) Collateral sensitivity to gemcitabine (2′,2′-difluorodeoxycytidine) and cytosine arabinoside of daunorubicin- and VM-26-resistant variants of human small cell lung cancer cell lines. Biochem Pharmacol 61: 1401-1408
7. Bergman AM, Pinedo HM, Peters GJ (2001b) Steroids affect collateral sensitivity to gemcitabine of multidrug-resistant human lung cancer cells. Eur J Pharmacol 416: 19-24
8. Bergman AM, Pinedo HM, Peters GJ (2002) Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist Update 5: 19-33
9. Bergman AM, Pinedo HM, Jongsma APM, Brouwer M, Ruiz van Haperen VWT, Veerman G, Leyva A, Eriksson S, Peters GJ (1999) Decreased resistance to gemcitabine of cytosine arabinoside resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase. Biochem Pharmacol 57: 397-406
10. Bergman AM, Ruiz van Haperen VWT, Veerman G, Kuiper CM, Peters GJ (1996) Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 2: 521-530
11. Birnboim HC, Jevcak JJ (1981) Fluorometic method for rapid detection of DNA strand breaks in human white blood cells produced by low doses of radiation. Cancer Res 41: 1889-1892
12. Borst P, Evers R, Kool M, Wijnholds J (2000) A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92: 1295-1302
13. Braakhuis BJM, Ruiz van Haperen VWT, Boven E, Veerman G, Peters GJ (1995) Schedule dependent antitumor effect of gemcitabine in in vivo model systems. Semin Oncol 22(Suppl 11): 42-46
14. Breuninger LM, Paul S, Gaughan K, Miki T, Chan A, Aaronson SA, Kruh GD (1995) Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res 55: 5342-5347
15. Clavy JS, Horwitz SB, Orr GA (1997) Identification of the in vivo phosphorylation sites for acidic-directed kinases in murine mdr1b P-glycoprotein. J Biol Chem 272: 5909-5914
16. Cornwell MM, Pastan I, Gottesman MM (1987) Certain calcium channel blockers bind specifically to multidrug resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem 262: 2166-2170
17. Davidson JD, Ma L, Iverson PW, Lesoon A, Jin S, Horwitz L, Gallery M, Slapak CA (2002) Human multi-drug resistance protein 5 (MRP5) confers resistance to gemcitabine. Proc Am Assoc Cancer Res 43: abstract 3868
18. Endicott JA, Ling V (1989) The biochemistry of P-glycoprotein-mediated multidrug resistance. Ann Rev Biochem 58: 137-171
19. Eriksson S, Kierszuk B, Munch-Petersen B, Oberg B, Johansson NG (1991) Comparison of the substrate specifities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs. Biochem Biophys Res Commun 176: 586-592
20. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SPC, Deeley RG (1994) Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 54: 357-361
21. Grant S, Turner A, Nelms P, Yanovich S (1995) Characterization of a multidrug resistant human erythroleukemia cell line (K562) exhibiting spontaneous resistance to 1-β-D-arabinofuranosylcytosine. Leukemia 9: 808-814
22. Hatzis P, Al-Madhoon AS, Jüllig M, Petrakis TG, Eriksson S, Talianidis I (1998) The intracellular localization of deoxycytidine kinase. J Biol Chem 273: 30239-30243
23. Heinemann V (2001) Gemcitabine: progress in the treatment of pancreatic cancer. Oncology 60: 8-18
24. Heinemann V, Hertel LW, Grindey GB, Plunkett W (1988) Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res 48: 4024-4031
25. Heinemann V, Schulz L, Issels RD, Plunkett W (1995) Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. Semin Oncol 22(4 Suppl 11): 11-18
26. Heinemann V, Xu Y-Z, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W (1990) Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 38: 567-572
27. Herzfield A, Raper SM (1980) Relative activities of thymidylate synthetase and thymidine kinase in rat tissues. Cancer Res 40: 744-750
28. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W (1991) Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51: 6110-6117
29. Jensen PB, Holm B, Sorensen M, Christensen IJ, Sehested M (1997) In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabine. Br J Cancer 75: 869-877
30. Keepers YP, Pizao PE, Peters GJ, Van Ark-Otte J, Winograd B, Pinedo HM (1991) Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing. Eur J Cancer 27: 897-900
31. Kuiper CM, Broxterman HJ, Baas F, Schuurhuis GJ, Haisma HJ, Scheffer GL, Lankelma J, Pinedo HM (1990) Drug transport variants without P-glycoprotein overexpression from a human squamous lung cancer cell line after selection with doxorubicin. J Cell Pharmacol 1: 35-41
32. Kroep JR, Loves WJP, Van der Wilt CL, Alvarez E, Talianidis I, Boven E, Braakhuis BJM, Van Groeningen CJ, Pinedo HM, Peters GJ (2002) Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther 1: 371-376
33. Lincke CR, Van der Bliek AM, Schuurhuis GJ, Van der Velde-Koerts T, Smit JJM, Borst P (1990) Multidrug-resistance phenotype of human BRO melanoma cells transfected with a wild-type human mdr1 complementary DNA. Cancer Res 50: 1779-1785
34. Louie KG, Hamilton TC, Winker MA, Behrens BC, Tsuruo T, Klecker RW, McKoy WM, Grotzinger KR, Myers CE, Young RC, Ozols RF (1986) Adriamycin accumulation and metabolism in adriamycin-sensitive and -resistant human ovarian cancer cell lines. Biochem Pharmacol 35: 467-472
35. Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP (1994) Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 86: 1530-1533
36. Ma L, Krishnamachary N, Center MS (1995) Phosphorylation of the multidrug resistance associated protein gene encoded protein P190. Biochemistry 34: 3338-3343
37. Mackey JR, Mani RS, Selner M, Mowle D, Young JD, Belt JA, Crawford CR, Cass CE (1998) Functional nucleoside transporters are required for gemcitabine influx and manifestations of toxicity in cancer cell lines. Cancer Res 58: 4349-4357
38. Mackey JR, Yao SY, Smith KM, Karpinski E, Baldwin SA, Cass CE, Young JD (1999) Gemcitabine transport in Xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. J Natl Cancer Inst 91: 1876-1881
39. Mulder HS, Pinedo HM, Timmer AT, Rao BR, Lankelma J (1996) Multidrug resistance-modifying components in human plasma with potential clinical significance. J Exp Therap Oncol 1: 13-22
40. Naray A, Aranyi P, Foldes I, Horvath I (1977) Analysis of thymidine kinase actvity and glucocorticoid binding capacity in the thymuses of healthy and tumor bearing chickens. J Natl Cancer Inst 59: 1237-1241
41. Peters GJ, Wets M, Keepers YPAM, Oskam R, Van Ark-Otte J, Noordhuis P, Smid K, Pinedo HM (1993) Transformation of mouse fibroblasts with the oncogenes H-ras or trk is associated with pronounced changes in drug sensitivity and metabolism. Int J Cancer 54: 450-455
42. Plunkett W, Huang O, Xu YZ, Heinemann V, Grunewald R, Ghandi V (1995) Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22(Suppl 11): 42-46
43. Ratnasinghe D, Phang JM, Yeh GC (1998) Differential expression and activity of phosphatases and protein kinases in adriamycin sensitive and resistant human breast cancer MCF-7 cells. Int J Oncol 13: 79-84
44. Rieger J, Durka S, Streffer J, Weller M (1999) Gemcitabine cytotoxicity of human malignant glioma cells: modulation by antioxidants, bcl-2 and dexamethasone. Eur J Pharmacol 365: 301-308
45. +-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib). J Biol Chem 276: 2914-2927
46. Rots MG, Willey JC, Jansen G, Van Zandwijk CH, Noordhuis P, DeMuth JP, Kuiper E, Veerman AJP, Pieters R, Peters GJ (2000) mRNA expression levels of methotrexate resistance related proteins in childhood leukemia as determined by a standardized competitive template based RT-PCR method. Leukemia 14: 2166-2175
47. Ruiz van Haperen VWT, Peters GJ (1994) New targets for pyrimidine antimetabolites for the treatment of solid tumours. II: Deoxycytidine kinase. Pharmacy World Sci 16: 104-112
48. Ruiz van Haperen VWT, Veerman G, Boven E, Noordhuis P, Vermorken JB, Peters GJ (1994) Schedule dependence of sensitivity of 2′,2′-difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumor cell lines and solid tumors. Biochem Pharmacol 48: 1327-1339
49. Ruiz van Haperen VWT, Veerman G, Braakhuis BJM, Vermorken JB, Boven E, Leyva A, Peters GJ (1993a) Deoxycytidine kinase and deoxycytidine deaminase activities in human tumour xenografts. Eur J Cancer 29A: 2132-2137
50. Ruiz van Haperen VWT, Veerman G, Vermorken JB, Peters GJ (1993b) 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA from tumour cell lines. Biochem Pharmacol 46: 762-766
51. Sasvári-Székely M, Spasokoukotskaja T, Szóke M, Csapó Z, Turi Á, Szántó I, Eriksson S, Staub M (1998) Activation of deoxycytidine kinase during inhibition of DNA synthesis by 2-chloro-2′-deoxyadenosine (Cladribine) in human lymphocytes. Biochem Pharmacol 56: 1175-1179
52. Schuurhuis GJ, Broxterman HJ, Ossenkoppele GJ, Baak JPA, Eekman CA, Kuiper CM, Feller N, Van Heijningen THM, Klumper E, Pieters R, Lankelma J, Pinedo HM (1995) Functional multidrug resistance phenotype associated with combined overexpression of PgP/MDR1 and MRP together with 1-β-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia. Clin Cancer Res 1: 81-93
53. Shen DW, Fojo A, Chin JE, Roninson IB, Richert N, Pastan I, Gottesman MM (1986) Human multidrug resistant cell lines: increased mdr1 expression can precede gene amplification. Science 232: 643-645
54. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR (1990) New calorimetric cytotoxicity assay for anticancer drug screening. J Natl Cancer Inst 82: 1107-1112
55. Smith CD, Zilfou JT (1995) Circumvention of P-glycoprotein mediated multiple drug resistance by phosphorylation modulators is independent of protein kinases. J Biol Chem 270: 28145-28152
56. Tesoriere G, Vento R, Taibi G, Calvaruso G, Schiavo MR (1989) Biochemical aspects of chick embryo retina development: the effects of glucocorticosteroids. J Neurochem 52: 1487-1494
57. Van der Wilt CL, Kroep JR, Bergman AM, Loves WJP, Alvarez E, Talianidis I, Van Groeningen CJ, Pinedo HM, Peters GJ (2000) The role of deoxycytidine kinase in gemcitabine cytotoxicity. Adv Exp Med Biol 486: 287-290
58. Van der Wilt CL, Visser GW, Braakhuis BJ, Wedzinga R, Noordhuis P, Smid K, Peters GJ (1993) In vitro antitumour activity of cis- and trans-5-fluoro-5,6-dihydro-6-alkoxy-uracils; effects on thymidylate synthesis. Br J Cancer 68: 702-707
59. Van Kalken CK, Broxterman HJ, Pinedo HM, Feller N, Dekker H, Lankelma J, Giaccone G (1993) Cortisol is transported by the multidrug resistance gene product P-glycoprotein. Br J Cancer 67: 284-289
60. Van Moorsel CJA, Pinedo HM, Veerman G, Bergman AM, Kuiper CM, Vermorken JB, Van der Vijgh WJ, Peters GJ (1999a) Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer 80: 981-990
61. Van Moorsel CJA, Pinedo HM, Veerman G, Guechev A, Smid K, Loves WJP, Veerman JB, Postmus PE, Peters GJ (1999b) Combination chemotherapy studies with gemcitabine and etoposide in non-small cell lung and ovarian cancer cell lines. Biochem Pharmacol 57: 407-415
62. Van Moorsel CJA, Bergman AM, Veerman G, Voorn DA, Ruiz van Haperen VWT, Kroep JR, Pinedo HM, Peters GJ (2000) Differential effects of gemcitabine on ribonucleotide pools of twenty-one solid tumour and leukaemia cell lines. Biochim Biophys Acta 1474: 5-12
63. Wang LM, Kucera GL (1994) Deoxycytidine kinase is phosphorylated in vitro by protein kinase C alpha. Biochem Biophys Acta 1224: 161-167
64. Wang L, Munch-Petersen B, Herrstrom Sjoberg A, Hellman U, Bergman T, Jornvall H, Eriksson S (1999) Human thymidine kinase 2: molecular cloning and characterisation of the enzyme activity with antiviral and cytostatic nucleoside substrates. FEBS Lett 443: 170-174
65. Zaman GJR, Flens MJ, Van Leusden MR, De Haas M, Mulder HS, Lankelma J, Scheper RJ, Baas F, Broxterman HJ, Borst P (1994) The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA 91: 8822-8826
66. Zaman GJR, Versantvoort CHM, Smit JJM, Eijdens EWHM, De Haas M, Smith AJ, Broxterman HJ, Mulder NH, De Vries EGE, Baas F, Borst P (1993) Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res 53: 1747-1750